Related by context. All words. (Click for frequent words.) 77 Aflibercept 76 Glufosfamide 75 Epidermal Growth Factor Receptor 75 Ofatumumab 75 Phase 2b Clinical Trial 75 CD# monoclonal antibody 75 Meets Primary Endpoint 75 Antitumor Activity 75 Relapsed Refractory 75 Daclizumab 75 Romiplostim 75 CYT# potent vascular disrupting 75 PEGylated Fab fragment 74 Aliskiren 74 oral prodrug 74 thalidomide Thalomid 74 Vicriviroc 74 Dasatinib 74 Diffuse Large B 74 Eculizumab 73 Phase 2b Trial 73 Novel Oral 73 Phase IIb Trial 73 Romidepsin 73 receptor tyrosine kinase inhibitor 73 erlotinib Tarceva ® 73 Cutaneous T 73 imatinib Gleevec ® 73 Anti Tumor 73 YONDELIS 73 Nilotinib 73 Pemetrexed 73 Hsp# Inhibitor 73 vapreotide acetate 73 Bosutinib 73 Pertuzumab 73 MAGE A3 ASCI 73 mapatumumab 73 Myelofibrosis 73 LymphoStat B belimumab 73 Complicated Skin 73 Voreloxin 72 Maribavir 72 metastatic malignant 72 PKC# 72 familial amyloidotic polyneuropathy FAP 72 Golimumab 72 Drug Candidate 72 dasatinib Sprycel ® 72 Deforolimus 72 Prolongs Survival 72 Bortezomib 72 rilonacept 72 Previously Untreated 72 Lenalidomide 72 pan HDAC inhibitor 72 Advanced Renal Cell 72 Previously Treated 72 Atypical Hemolytic Uremic Syndrome 72 Pivotal Study 72 histone deacetylase HDAC inhibitor 72 Malignant Melanoma 72 Metastatic Colorectal Cancer 72 Advanced Melanoma 72 Boceprevir 72 Monoclonal Antibody 72 Omacetaxine 72 Anti Tumor Activity 72 Initiate Clinical Trial 72 Zorbtive TM 72 Patients Treated With 72 Traficet EN 72 Chronic Hepatitis C 72 Tezampanel 72 Safinamide 71 Myelodysplastic Syndrome MDS 71 Pharmacokinetics PK 71 refractory chronic lymphocytic 71 Blinatumomab 71 FOLOTYN ® 71 Fludarabine 71 Chronic Myeloid Leukemia 71 Vidaza azacitidine 71 Bevacizumab 71 myelofibrosis polycythemia vera 71 Sapacitabine 71 PNP inhibitor 71 proteasome inhibitor 71 dasatinib Sprycel 71 Adjuvant Treatment 71 alfa 2a 71 oncolytic virus therapies 71 sunitinib Sutent ® 71 leukemia AML 71 investigational monoclonal antibody 71 HuMax EGFr 71 mTOR inhibitor 71 antibody MAb 71 Receives Orphan Drug Designation 71 SPRYCEL ® 71 Denufosol 71 gefitinib Iressa 71 Carfilzomib 71 Gleevec resistant 71 Iloperidone 71 Unresectable 71 Chronic Lymphocytic Leukemia 71 Ocrelizumab 71 Well Tolerated 71 Initiates Enrollment 71 Vitaxin 71 Decitabine 71 GW# [003] 71 Nitazoxanide 71 Aplidin R 71 nucleoside analog 71 Phase 2a Clinical Trial 71 evaluating tivozanib 71 Enzastaurin 71 Initiates Clinical 71 Xanafide 71 cell lymphoma CTCL 71 Dapagliflozin 71 Diabetic Nephropathy 71 Aplidin 71 Diabetic Neuropathy 71 Gleevec imatinib mesylate 71 Adalimumab 71 MGd 71 nilotinib Tasigna 71 beta 1a 71 Pazopanib 71 Ozarelix 71 Improved Survival 71 Pooled Analysis 70 Alemtuzumab 70 Investigational Drug 70 Oral Fingolimod 70 NS#/#A protease 70 Noxafil 70 Zarnestra 70 IMA# 70 Study Evaluating 70 Metastatic Melanoma 70 HuMax CD4 70 Investigational Treatment 70 Luteinizing Hormone Releasing Hormone 70 Tesetaxel 70 protein tyrosine phosphatase 1B 70 fosbretabulin 70 Personalized Immunotherapy 70 Pirfenidone 70 MKC# MT 70 Belimumab 70 Achieves Primary Endpoint 70 Liposomal 70 Bucindolol 70 Clinical Trial Results 70 Granted Orphan Drug 70 Preclinical Study 70 Survival Benefit 70 Tumor Necrosis Factor 70 Gefitinib 70 Single Dose 70 Newly Diagnosed Multiple Myeloma 70 docetaxel Taxotere R 70 Pulmonary Arterial Hypertension 70 Azacitidine 70 Amrubicin 70 Tyrosine Kinase Inhibitor 70 HDAC Inhibitor 70 panitumumab Vectibix 70 Severe Sepsis 70 Zolinza 70 Selective Inhibitor 70 formerly LymphoStat B 70 SinuNase TM 70 targeted radiotherapeutic 70 Temsirolimus 70 Relapsing Remitting Multiple Sclerosis 70 Relapsed Multiple Myeloma 70 Hormone Refractory Prostate Cancer 70 Combination REOLYSIN R 70 follicular Non Hodgkin 70 Bavituximab 70 Peginterferon alfa 2b 70 HQK 70 Monotherapy 70 Renal Cell Carcinoma 70 developing Bicifadine serotonin 70 Rituximab 70 TNF Tumor Necrosis Factor 70 R Saizen R 70 etanercept Enbrel 70 Fulvestrant 70 brand ciclesonide HFA 70 First Patient Dosed 70 Improves Survival 70 Phase III Trial 70 Elagolix 70 Degarelix 70 targeting CD# 70 Annamycin 70 Investigational Compound 70 Presents Preclinical Data 70 Initiate Phase 70 galiximab 70 Nucleoside 70 orally administered inhibitor 70 Ridaforolimus 70 relapsed MM 70 Archexin 70 Preclinical Data 70 Elotuzumab 70 Therapeutic Vaccine 70 Anthracycline 70 IMiDs ® compound 70 elotuzumab 70 vinca alkaloid 70 refractory gout 70 Soft Tissue Sarcoma 70 Long Term Efficacy 70 Humanized Anti 70 Improves Outcomes 70 humanized anti 70 baminercept 70 IMiDs ® 70 trastuzumab Herceptin R 70 Recombinant Human 70 Aurora Kinase 70 Pharmacokinetic Study 70 Factor VIIa 70 Irinotecan 70 Castration Resistant Prostate Cancer 70 Completes Patient Enrollment 70 Vidaza R 70 Fludara ® 70 multi kinase inhibitor 70 Apaziquone 69 Pafuramidine 69 Antitumor 69 CTAP# Capsules 69 Mipomersen 69 Plaque Psoriasis 69 invasive candidiasis 69 Antiviral Activity 69 Leukemias 69 T#I [002] 69 IgG1 monoclonal antibody 69 Enzyme Replacement Therapy 69 Trabectedin 69 MKC# MKC# PP 69 non nucleoside inhibitor 69 liposomal formulation 69 Immunotherapeutic 69 Navelbine ® 69 Peginterferon Alfa 2a 69 CD3 monoclonal antibody 69 CYP#A# CYP#D# 69 AVASTIN 69 MEK Inhibitor 69 Randomized Phase 69 Lacosamide 69 Anti VEGF 69 adalimumab Humira 69 LymphoStat B TM 69 sorafenib Nexavar 69 Interferon Gamma 69 Alocrest 69 Melphalan 69 BRAF inhibitor 69 hypereosinophilic syndrome 69 Peginterferon 69 methylnaltrexone bromide 69 sunitinib Sutent 69 Orally Active 69 Erlotinib 69 Adjuvant Chemotherapy 69 sorafenib tablets 69 Dacogen decitabine 69 Vandetanib 69 Methylnaltrexone 69 Phase IIa Clinical Trial 69 Fast Track Status 69 PEGylated anti 69 Pivotal Phase 69 Genentech Rituxan 69 Ambrisentan 69 riociguat 69 investigational humanized monoclonal antibody 69 cetuximab Erbitux R 69 Candesartan 69 mertansine 69 investigational oral inhibitor 69 Trastuzumab 69 Sipuleucel T 69 docetaxel Taxotere ® 69 MT#/MEDI-# 69 Protease Inhibitor 69 Darinaparsin 69 metaglidasen 69 Pivotal Phase II 69 chimeric monoclonal antibody 69 ADP receptor antagonist 69 Efficacy Trial 69 Phase III Trials 69 telomerase therapeutic 69 Silodosin 69 ara C 69 Ixabepilone 69 chronic eosinophilic leukemia 69 kidney urologic 69 alkylating agent 69 5 HT6 receptor 69 Interferon Beta 69 Pivotal Phase III 69 cilengitide 69 atypical Hemolytic Uremic Syndrome 69 XL# XL# 69 CYC# 69 Kinase Inhibitors 69 Philadelphia Chromosome Positive 69 Pralatrexate 69 Ribavirin causes 69 Kahalalide F 69 gastrointestinal stromal tumors GIST 69 Vidofludimus 69 canakinumab 69 Brentuximab Vedotin SGN 69 R bendamustine hydrochloride 69 metastatic colorectal 69 Ceflatonin R 69 Kinase Inhibitor 69 sodium glucose cotransporter 69 PI3K/Akt pathway inhibitor 69 Cell Lymphoma 69 Antiangiogenic 69 AKT inhibitor 69 Mycophenolate Mofetil 69 JAK Inhibitor 69 Myelodysplastic Syndromes 69 Trial Evaluating 69 VICTOR E3 69 systemic anaplastic large 69 Thiarabine 69 Infected Patients 69 huC# DM4 69 lumiliximab 69 Treatment Naïve 69 Cethromycin 69 virus HCV protease inhibitor 69 Angioedema 69 Interferon beta 1a 69 Teriflunomide 69 FOLFOX6 69 Paraplatin ® 69 Pegloticase 69 refractory cutaneous T 69 Talabostat 69 Phase III Clinical Trial 69 Refractory Hodgkin Lymphoma 69 humanized monoclonal antibody 69 Velcade bortezomib 69 cetuximab Erbitux ® 69 EGFR TKI 69 Bezielle 69 Dose Escalation 69 CD# CEA 69 Novel Mechanism 69 advanced metastatic renal 69 IMiDs R 69 Vaccine Adjuvant 69 cancer vaccine Norelin 69 paclitaxel Taxol 69 Lupus Nephritis 69 Glatiramer Acetate 69 Autologous Stem Cell Transplantation 69 multiple myeloma MM 69 idiopathic thrombocytopenic purpura ITP 69 HGS ETR2 68 Novel Antibiotic 68 Tigecycline 68 Bafetinib 68 leukemia CLL 68 Amgen Neulasta R 68 Catena ® 68 Disease Progression 68 Randomized Double blind 68 Janus kinase 68 dextromethorphan quinidine 68 Mitoxantrone 68 XmAb# 68 miconazole Lauriad ® 68 JAK2 Inhibitor 68 OMP #M# 68 MyVax R 68 basiliximab 68 pegylated liposomal doxorubicin 68 Cloretazine ® 68 Zalypsis 68 intranasal formulation 68 Valsartan 68 Files IND 68 highly selective endothelin 68 Acute Ischemic Stroke 68 Etanercept 68 bortezomib Velcade 68 OncoVex 68 Hormone Receptor Positive 68 Hedgehog Pathway Inhibitor 68 Metastatic Prostate Cancer 68 Tanespimycin 68 SYN# 68 imatinib Gleevec 68 II Clinical Trial 68 Onalta 68 Adjuvant Therapy 68 Pegylated Interferon 68 Aurora kinase 68 recurrent glioblastoma multiforme 68 Campath alemtuzumab 68 Investigational Agent 68 Chronic Lymphocytic Leukemia CLL 68 Valopicitabine 68 plasma kallikrein inhibitor 68 K ras mutations 68 Panzem R NCD 68 ISTODAX ® 68 Lung Cancer Drug 68 tumor xenograft models 68 small molecule Hedgehog 68 Metastatic Renal Cell Carcinoma 68 Oral Cladribine 68 Xeloda ® 68 Sym# 68 posaconazole 68 Proxinium TM 68 Plecanatide 68 Naive Patients 68 Leukine ® 68 TYZEKA 68 reslizumab 68 Shows Efficacy 68 Chronic Hepatitis B 68 oral antiviral 68 Demonstrates Positive 68 PXD# 68 KRN# 68 IMiD 68 ZACTIMA 68 Rilonacept 68 BAL# [002] 68 vinorelbine tartrate 68 Phase 2a Trial 68 INSPIRE Trial Phase III 68 Ceftaroline 68 Quinamed 68 erlotinib Tarceva R 68 polymerase inhibitor 68 diarrhea predominant irritable 68 Tarceva TM 68 lenalidomide Revlimid R 68 Pegylated 68 Mg Usa 68 investigational pharmacologically unique 68 AA Amyloidosis 68 Multiple Myeloma MM 68 Chronic Sinusitis 68 Phase IIb Clinical Trial 68 Phase 1b clinical trials 68 romidepsin 68 STELARA TM 68 ceftazidime 68 Myelodysplastic Syndrome 68 Kepivance 68 Lymphocytic 68 Kuvan sapropterin dihydrochloride 68 PRTX 68 Thiovir 68 tigecycline 68 Patient Enrollment 68 denileukin diftitox 68 hA# 68 myelodysplastic myeloproliferative diseases 68 Certolizumab 68 NDA Submission 68 IAP inhibitor 68 receptor modulators 68 Perifosine 68 acadesine 68 ofatumumab HuMax CD# 68 velafermin 68 Granulocyte Colony Stimulating Factor 68 interleukin IL -# 68 Pivotal Trial 68 Initiates Clinical Trial 68 ATL/TV# 68 tocilizumab 68 dual endothelin receptor antagonist 68 Aptivus ® 68 Initiates Phase III 68 generation purine nucleoside 68 AZT zidovudine Retrovir 68 FDA APPROVES 68 bevacizumab Avastin ® 68 demonstrated antitumor activity 68 SNT-MC#/idebenone 68 Fluorouracil 68 indolent NHL 68 cediranib 68 imatinib resistant 68 ® bortezomib 68 Otelixizumab 68 DFMO 68 phase III isavuconazole 68 Xcytrin R 68 lymphoid malignancies 68 Initiates Phase II 68 RAF kinase 68 R sorafenib tablets 68 Phase 2b Study 68 Palifosfamide 68 agonistic human 68 Polymerase Inhibitor 68 AEG# 68 Crizotinib 68 Eltrombopag 68 endothelin receptor 68 Intravenous Human 68 metastatic castration resistant 68 Onconase 68 Pathway Inhibitor 68 atypical hemolytic uremic syndrome 68 Lenocta TM 68 Tocilizumab 68 AAG geldanamycin analog 68 NAGS deficiency 68 interferon gamma 1b 68 alefacept 68 Receives Orphan Drug 68 solithromycin 68 Is Well Tolerated 68 Dendritic Cells 68 SinuNase ™ 68 cutaneous T 68 Vitro Activity 68 Successfully Completes Phase 68 Panzem R 68 Metabolic Disorder 68 tyrosine kinase inhibitor 68 Bendamustine 68 bevacizumab Avastin R 68 pertuzumab 68 metastatic neuroendocrine tumors 68 Lenocta 68 Lupus Drug 68 EGFr 68 PRN FDA Approves 68 visilizumab 68 Dalbavancin 68 Platinol ® 68 Dacogen injection 68 leukemia ALL 68 radiation sensitizer 68 Estrogen Receptor 68 phase IIb trial 68 Glioblastoma Multiforme 68 mycophenolate mofetil 68 RNAi Therapeutic 68 Double Blind Placebo 68 acyclovir Lauriad R 68 Follicular Lymphoma 68 SCCHN 68 OHR/AVR# 68 erlotinib Tarceva 68 Onco TCS 68 Cardiotoxicity 67 IV Busulfex 67 ospemifene 67 MCSP respectively 67 EOquin TM 67 Antithrombin 67 idarubicin 67 Chemoradiation 67 Vidaza ® 67 Xelox 67 pralatrexate injection folate analogue 67 Kinoid 67 Radioimmunotherapy 67 YONDELIS R 67 Phase #b/#a clinical 67 ularitide 67 Antiviral Therapy 67 volociximab 67 mild vasodilator 67 Hepatocellular Carcinoma 67 Drug Shows Promise 67 Antitumor activity 67 monoclonal antibody conjugated 67 Study Showed 67 orally bioavailable 67 candidates Azedra 67 IAP inhibitors 67 MT# MEDI 67 bendamustine 67 Muraglitazar 67 complement inhibitor eculizumab 67 acetonide FA 67 Diabetic Macular Edema 67 gastrointestinal stromal tumors GISTs 67 Targeted Therapy 67 Cholesterol Lowering Drug 67 Androgen Receptor 67 pathophysiological effects 67 PRT# 67 pharmacokinetic interactions 67 Nexavar sorafenib 67 Efficacy Results 67 Nanobody 67 vidofludimus 67 PSMA ADC 67 triciribine phosphate monohydrate 67 TBC# 67 recurrent NSCLC 67 Patients Receiving 67 Medullary Thyroid Cancer 67 Cardiomyocytes 67 CML CP 67 Demonstrates Significant 67 Sudhir Agrawal D.Phil 67 Completes Enrollment 67 Myeloma Patients 67 Gemzar ® 67 ritonavir boosted 67 ZEVALIN ® 67 Neuvenge 67 Telbivudine 67 Arcalyst 67 selective antagonist 67 Vfend 67 Ustekinumab 67 Ibritumomab Tiuxetan 67 Telintra 67 Lubiprostone 67 XYOTAX TM 67 Advanced Pancreatic Cancer 67 SNT MC# 67 oral dual endothelin 67 oral proteasome inhibitor 67 Preclinical Models 67 CIMZIA TM 67 selective modulator 67 Novel Inhibitor 67 angiogenesis inhibitor 67 Replacement Therapy 67 gemcitabine Gemzar ® 67 humanized monoclonal 67 Tasigna nilotinib 67 Hematological Malignancies 67 Mantle Cell Lymphoma 67 efalizumab 67 Racivir 67 gemcitabine Gemzar 67 Medoxomil 67 HuLuc# 67 Ceflatonin 67 Crofelemer budesonide foam 67 HGS ETR1 67 small molecule thrombopoietin 67 CD4 monoclonal antibody 67 OMP #R# 67 Abiraterone acetate 67 DEB# 67 Potent Antiviral Activity 67 NS5b 67 stage IIIB 67 Dose Ranging Study 67 FUSILEV enhances 67 PDX pralatrexate 67 bevacizumab Avastin 67 Hodgkin lymphoma NHL 67 ALN HPN 67 TRAIL R2 67 pancytopenia 67 JAK inhibitor 67 aflibercept VEGF Trap 67 Tipranavir 67 cancer immunotherapies 67 Initiate Phase III 67 severe hypersensitivity reactions 67 selective agonist 67 efaproxiral 67 Relapsing Multiple Sclerosis 67 BAY #-# 67 Febuxostat 67 Combination Therapy 67 humanized antibody 67 PEGylated interferon beta 1a 67 Treatment Naive Patients 67 Interferon Alpha 67 Systemic Delivery 67 Everolimus 67 BENLYSTA TM 67 paclitaxel Taxol ® 67 PEG IFN 67 Raptiva ® 67 Monoclonal 67 Fingolimod 67 Treatment Experienced 67 BARACLUDE ® 67 Symadex 67 Doripenem 67 PEG SN# 67 Protease Inhibitors 67 ribavirin RBV 67 Begins Dosing 67 Daptomycin 67 HER2 Positive Breast Cancer 67 BARACLUDE R 67 Kit CD# positive 67 FOLFOX6 chemotherapy regimen 67 Adenoviral 67 castrate resistant prostate cancer 67 ThermoDox ® clinical 67 Anidulafungin 67 Statistically Significant 67 FDA Okays 67 SAR# [004] 67 #I TM# 67 Cetrorelix 67 PEGylated interferon 67 CBLC# 67 phase IIb clinical 67 Receptor Agonist 67 Fondaparinux 67 Psoriasis Drug 67 HCV Protease Inhibitor 67 tumor lysis syndrome 67 Cloretazine 67 Rituxan rituximab 67 Vitrasert R 67 personalized cellular immunotherapy 67 TORISEL 67 ® lenalidomide 67 5 HT4 67 Receptor Antagonists 67 pentostatin 67 Novel Compound 67 EGFr humanized monoclonal antibody 67 Albuferon TM 67 ALN TTR 67 pediatric acute lymphoblastic 67 DAVANAT 67 TO AVOID PREGNANCY WHILE 67 Oral Mucositis 67 INCB# [003] 67 CIMZIA ™ 67 metastatic renal cell carcinoma 67 Diabetic Macular Edema DME 67 Rheumatoid Arthritis RA 67 Anticancer Agent 67 benign prostatic hypertrophy BPH 67 5 FU leucovorin 67 alpha#beta# integrin 67 MTP inhibitor 67 MELAS 67 Prospective Randomized 67 Factor Receptor 67 PROCRIT ® 67 Milestone Payment 67 Mg Uk 67 Ovitrelle R Serostim 67 relapsing multiple sclerosis 67 Chemokine Receptor 67 Novel Therapeutic 67 HER2 overexpression 67 COPEGUS R 67 Saforis 67 highly selective inhibitor 67 DermaVir Patch 67 UPLYSO 67 mGluR5 negative 67 Shows Promise Against 67 Serious Infections 67 neutropenia dehydration dyspnea 67 Exherin TM 67 Capecitabine 67 Demonstrates Potent 67 multikinase inhibitor 67 dependent kinase inhibitor 67 Xcellerated T Cells 67 ATL# [001] 67 CCR5 antagonist 67 FDA Accepts 67 Fungal Infections 67 trabectedin 67 lucinactant 67 relapsed multiple myeloma 67 antibody trastuzumab 67 Copegus ribavirin 67 selective kinase inhibitor 67 Combination Treatment 67 depsipeptide 67 Cerebril TM 67 TMC# C# 67 induced macular edema 67 arsenic trioxide injection 67 Demonstrates Efficacy 67 flavopiridol 67 Neulasta ® 67 Antibody Drug Conjugate 67 Chronic Myelogenous Leukemia CML 67 ORENCIA ® 67 mTOR mammalian target 67 cMET 67 BCG refractory carcinoma 66 Fc fusion protein 66 Gastrointestinal Stromal Tumors 66 esophageal candidiasis 66 selective androgen receptor modulator 66 plus DOXIL 66 icatibant 66 Colorectal Cancer Patients 66 R lenalidomide 66 NICE Recommends 66 Anticancer Drugs 66 Progressive Multifocal Leukoencephalopathy 66 Phase III Pivotal 66 trastuzumab DM1 T DM1 66 RhuDex 66 Nicotine Vaccine 66 Shows Statistically Significant 66 abacavir Ziagen 66 Rheumatoid Arthritis Drug 66 Alinia 66 CHOP chemotherapy 66 relapsed leukemia 66 RhuDex R 66 GVAX ® 66 ALVESCO ® 66 ABLYNX 66 Antigen Specific 66 Intravitreal 66 NS5B polymerase 66 TNFalpha 66 Keryx Biopharma 66 ixabepilone 66 Elesclomol 66 anti EGFR antibody 66 Tarceva erlotinib 66 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 66 Cloretazine VNP#M 66 Mouse Model 66 HSP# inhibitor 66 intravesical infusion therapy 66 Squalamine 66 Toxicities 66 BZL# 66 Evoltra ® 66 essential thrombocythemia ET 66 bortezomib Velcade R 66 Virulizin ® 66 Amplimexon 66 carcinoma mCRC 66 Advanced Prostate Cancer 66 liposomal doxorubicin 66 mesylate 66 Cyclophosphamide 66 Renal Cancer 66 constipation predominant irritable bowel 66 Aptamer 66 Alfacell proprietary ribonuclease 66 eltrombopag 66 rhIL 7 66 Nexavar ® 66 KNS # 66 D aspartate NMDA receptor 66 OXi# 66 FLT3 66 Telaprevir VX 66 selective orally bioavailable 66 Phase 1b Clinical Trial 66 gastrointestinal stromal tumor GIST 66 vemurafenib 66 BiovaxID TM 66 Idiopathic Pulmonary Fibrosis 66 Azedra 66 rufinamide 66 amprenavir 66 CCX# 66 pemphigus vulgaris 66 Squamous 66 Solazed TM 66 lintuzumab SGN 66 Pimavanserin 66 induce orthostatic hypotension 66 Relapsed Refractory Aggressive 66 Vaprisol 66 PEGINTRON TM 66 Vildagliptin 66 Immunogenic 66 ocular formulation 66 cyclophosphamide doxorubicin vincristine 66 lexidronam injection 66 Prostate Cancer Vaccine 66 Isavuconazole 66 luteinizing hormone releasing 66 Vorinostat 66 alpha 2a 66 indolent follicular non 66 allosteric modulator NAM 66 ThermoDox R 66 HCD# [002] 66 VitiGam 66 humanized interleukin 6 66 oral dihydropyrimidine dehydrogenase DPD 66 Known hypersensitivity 66 Rigel R# 66 Topline Results 66 Immunomodulatory 66 cutaneous T cell 66 oral Janus kinase 66 Solid Tumors 66 HuMax CD# 66 mGluR5 NAM 66 Darunavir 66 Ziprasidone 66 Treated Patients 66 DOXIL 66 Avastin bevacizumab 66 ACZ# 66 HGS# 66 Cariprazine 66 novel topoisomerase 66 TREANDA 66 Orally administered 66 Pegasys ® 66 docetaxel Taxotere 66 mGluR2 positive 66 Cell Non Hodgkin 66 Placebo Controlled Trial 66 potent cytotoxic 66 Present Preclinical Data 66 B Cell Lymphoma 66 pseudobulbar affect PBA 66 non metastatic osteosarcoma 66 candidates Azedra TM 66 Elvitegravir 66 effector function 66 ZOLINZA 66 azacytidine 66 MEK inhibitor 66 teriflunomide 66 HGS ETR1 mapatumumab 66 TACI Ig 66 Panzem 66 hypoxia inducible factor 66 Hematologic 66 XL# anticancer compounds 66 pomalidomide 66 Receptor Antagonist 66 Herceptin trastuzumab 66 ALVESCO R 66 small molecule tyrosine 66 Serostim R 66 Oncolytic 66 Onalta ™ 66 pharmacokinetic PK study 66 recurrent metastatic ovarian cancer 66 TTR gene 66 OMNARIS HFA 66 Tasimelteon 66 Clofarabine 66 Natalizumab 66 Allogeneic 66 occlusion PAO 66 systemic fungal infections 66 Respiratory Syncytial Virus RSV 66 Pradefovir 66 fluoropyrimidine 66 Dupuytren Contracture 66 investigational immunotherapy 66 investigational protease inhibitor 66 MYCAMINE 66 somatostatin analog 66 Paclitaxel Carboplatin 66 Liprotamase 66 leukemia CML 66 Imprime PGG 66 Friedreich Ataxia FRDA 66 sargramostim 66 humanised monoclonal antibody 66 gemcitabine carboplatin 66 PANVAC VF 66 Overactive Bladder 66 Certolizumab pegol 66 VEGFR2 inhibitor 66 Prodarsan R 66 CYP#A# substrate